MIST Trial to Evaluate Oral ECC4703 and Semaglutide for Body Weight and Liver Fat Reduction
Background
Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), formerly NAFLD, represent significant global health challenges, often co-occurring and contributing to increased cardiovascular risk and mortality. Current treatments for obesity, including GLP-1 receptor agonists like semaglutide, have shown efficacy in weight loss and improving metabolic parameters. However, there remains a need for enhanced therapeutic strategies, particularly those that can more directly target hepatic fat accumulation. Thyroid hormone receptor beta (THR-β) agonists are emerging as promising agents for MASLD due to their ability to selectively activate the THR-β isoform in the liver, promoting fatty acid oxidation and reducing lipogenesis, thereby offering a complementary mechanism to GLP-1 agonism.
Study Design
The MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) trial is designed as a clinical study to evaluate the effects of oral ECC4703 in combination with semaglutide. The primary objective is to assess the effect of oral ECC4703 on body weight reduction. A sub-study will evaluate changes in liver fat content, quantified by magnetic resonance imaging proton density fat fraction (MRI-PDFF), at Week 20. Further assessment of liver fat content and the percentage of participants achieving at least a 30% relative reduction in liver fat from baseline will be conducted after 48 weeks of planned maintenance treatment.
Results
This record describes the design and objectives of the MIST trial, which is currently planned or ongoing. As such, specific results, statistical outcomes, and quantitative findings are not yet available. The trial aims to generate data on body weight reduction and improvements in liver fat content as assessed by MRI-PDFF at Week 20 and Week 48. The primary endpoint focuses on body weight changes, while a key secondary endpoint will measure the absolute change in liver fat content and the proportion of participants achieving a clinically significant 30% relative reduction in liver fat. No numerical data, p-values, or fold-changes can be reported at this stage, as the study has not yet published its findings. Therefore, no specific results can be quoted or highlighted.
Key Findings
- Trial aims to evaluate oral ECC4703 with semaglutide for body weight reduction.
- Sub-study will assess liver fat content via
MRI-PDFFat Week 20 and Week 48. - Primary outcome is body weight reduction, with liver fat as a key secondary outcome.
- Improvement in liver fat defined as at least 30% relative reduction from baseline.
Why It Matters
The MIST trial, if successful, could establish a novel combination therapy for obesity and MASLD, potentially offering superior outcomes compared to monotherapy. Combining a GLP-1 agonist like semaglutide with a THR-β agonist like ECC4703 could provide synergistic benefits, addressing both systemic metabolic dysfunction and targeted hepatic fat reduction. This approach could lead to more comprehensive improvements in metabolic health, beyond what GLP-1 agonists achieve alone. For individuals struggling with both conditions, this combination might offer a more effective protocol, potentially impacting future clinical guidelines and expanding therapeutic options for a broader patient population. The trial's focus on an oral THR-β agonist also highlights the potential for convenient, non-injectable treatment regimens.
semaglutide
ecc4703
obesity
masld
clinical-trial
glp-1-agonist